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Background: ANCA associated vasculitis (AAV) is an autoimmune disease with significant morbidity and mortality,
in which diagnostic delay is associated with worse outcomes. AAV is rarely found in association with other immune
mediated diseases. Early recognition of such overlaps enables more timely diagnosis and may impact on disease
outcome. We reviewed cases of AAV in which there was an overlap with rheumatoid arthritis (RA).
Methods: We performed a retrospective analysis of our vasculitis database for patients who had a diagnosis of AAV
and RA, and a literature search to find other reported cases of this overlap syndrome.
Results: We found six subjects who had a diagnosis of RA and developed AAV at a median of 10.5 years (range
4–43 years) after the diagnosis of RA. They had been treated with a mean of 2 disease modifying drugs (0–4) and
all had evidence of renal involvement with median creatinine of 227 μmol/l (range 128–700 μmol/l). Only one had
a diagnosis of granulomatosis with polyangiitis, while the rest had a clinical diagnosis of microscopic polyangiitis.
Half of the patients had positive rheumatoid factor (RhF) at the time of vasculitis diagnosis, three had MPO-ANCA,
one PR3-ANCA, and two had ANCA-negative pauci-immune vasculitis. Additionally, we found 29 other cases reported
of this overlap, which also most frequently presented with vasculitic renal manifestations, and were frequently RhF
positive at the time of AAV diagnosis.
Conclusions: AAV occurs in subjects with RA rarely, and often with significant delay from the first rheumatological
manifestations. Renal involvement is common
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Anti-neutrophil cytoplasm antibody (ANCA) associated
Vasculitis (AAV) comprises 3 different clinical entities:
granulomatosis with polyangiitis(GPA, formerly Wegener’s
granulomatosis ), microscopic polyangiitis (MPA) and
eosinophilic granulomatosis with polyangiitis (EGPA, for-
merly Churg-Strauss syndrome ). These clinical syndromes
are frequently (but not always) characterized by ANCA
reactive against one of two antigens, proteinase-3 (PR3)
or myeloperoxidase (MPO), the former more commonly
associated with GPA and the latter more frequently found
in patients with MPA and EGPA (Finkielman et al. 2007).
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reproduction in any medium, provided the origAAV subsets have recently been described through gen-
ome wide association studies and appear to be different
between PR3-and MPO-AAV, with the most significant
associations with HLA genes, implicated in other auto-
immune diseases. (Lyons et al. 2012) Clinically, AAV may
rarely be associated with other immune mediated diseases,
those that have been well recognized include anti-
glomerular basement membrane (GBM) disease (Weber
et al. 1992; Kalluri et al. 1997), scleroderma (Derrett-Smith
et al. 2013), systemic lupus erythematosus(Tetikkurt et al.
2012) and membranous glomerulonephritis(Gaber et al.
1993; Tse et al. 1997). Knowledge of these overlap syn-
dromes is important in early recognition of potential
complications and differences in clinical courses and
management pathways.his is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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group of patients with Rheumatoid arthritis (RA), where
there has been a delay in presentation with vasculitic
symptoms following the diagnosis of RA. Here we describe
our cohort of patients presenting over the last 10 years
and review the literature describing this less well known
association. We suggest that recognition of this overlap is
important for more effective serological screening and
early recognition of potential clinical complications.
Case 1
A 59 year old male patient was diagnosed with seronega-
tive RA and received treatment with methotrexate (MTX)
and prednisolone. Four years after the diagnosis of RA, he
presented with a productive cough, haematuria, protein-
uria (6.84 g/24 hours) and decline in renal function (serum
creatinine (SCr) rising from 119 to 270 mmol/L). He had
an acute phase response (CRP 33 mg/L, ESR 134 mm/h)
and was PR3-ANCA positive (67 U/ml, normal range
0–3). The RhF and anti-CCP remained negative. A CT
scan of the chest showed multiple air filled cavitating
structures and CT scan of his sinuses revealed extensive
bony defects in the antronasal regions and thickening of
the maxillary and frontal sinuses. A kidney biopsy demon-
strated focal necrotising vasculitis lesions. As a result a
diagnosis of Granulomatosis with polyangiitis(GPA) was
made and he was treated with pulsed methylprednisolone,
oral prednisolone and intravenous cyclophosphamide. His
renal function improved (SCr 115, proteinuria 0.58 g/
24 hours) and his pulmonary lesions regressed.
Case 2
A 54 year old woman diagnosed with seropositive RA
after a symmetrical polyarthritis of the metacarpopha-
langeal joints, wrists and knees developed. She received
treatment with infliximab and subsequently MTX and
sulphasalazine because of poor disease control. Fourteen
years later, she developed acute renal failure (SCr
243 μmol/L) with haematuria and proteinuria (4.58 g/
24 hours), elevated acute inflammatory markers (CRP
113 mg/L, ESR 124 mm/h) and anti-MPO positivity
(>100 U/ml, NR <10). RhF was highly positive (214 IU/
ml, normal range 0–20) as was anti-CCP. Kidney biopsy
revealed focal and segmental necrotising glomerulo-
nephritis, with moderate chronic damage. A diagnosis of
microscopic polyangiitis(MPA) was made. She was treated
with methylprednisolone, oral prednisolone and intraven-
ous pulsed cyclophosphamide and had an improvement in
her renal function (SCr 198 μmol/L), proteinuria (0.5 g/
24 hours), and CRP (8 mg/L).
Case 3
A 33 year old woman was diagnosed with seronegative
RA. She was intolerant of methotrexate, sulphasalazineand azathioprine, and was treated with etanercept with
improvement in her symptoms. Thirty four years later,
she developed a vasculitic rash on her legs, and was
noted to have acute kidney injury (SCr 211 μmol/L),
haematuria and proteinuria (1.55 g/24 hours). She was
ANCA negative, but a renal biopsy demonstrated pauci-
immune focal necrotizing glomerulonephritis with mod-
erate chronic damage. She was diagnosed with MPA and
treated with pulsed methylprednisolone, oral prednisol-
one and pulsed intravenous cyclophosphamide, following
which she had an improvement of renal function (SCr
129 μmol/L) and proteinuria (0.3 g/24 hours).
Case 4
A 24 year old woman was diagnosed with seronegative
RA for which she had therapy with prednisolone. Forty-
three years later she was referred to our hospital with
declining renal function (SCr 128 mmol/L), associated
with proteinuria. Her serum inflammatory markers were
elevated (CRP 36 mg/L, ESR 57 mm/h) and MPO-
ANCA was positive (124 U/ml), as was her RhF (64 IU/
ml, normal range 0–20). A renal biopsy demonstrated
focal and segmental necrotising glomerulonephritis with
a background chronic parenchymal damage. A diagnosis
of MPA was made. She was treated with oral prednisol-
one and azathioprine, and had an improvement in her
renal function (sCr 99 μmol/L), and reduction in MPO-
ANCA titer (11 IU/ml).
Case 5
A 63 year old man was diagnosed with seropositive RA
affecting his knees and shoulders and was treated with
sulphasalazine. Six years after the diagnosis of RA, he
presented with haematuria, proteinuria (2.16 g/24 hours)
and decline in renal function (SCr rising from 73 to
148 μmol/L). He had an acute phase response (CRP
70 mg/L, ESR 65 mm/h) and was MPO-ANCA positive
(100 IU/ml, normal range 0–6). The RhF was positive
(75.5 IU/ml, normal range 0–20). A kidney biopsy dem-
onstrated focal necrotising vasculitic lesions. A diagnosis
of MPA was made and he was treated with oral prednis-
olone and mycophenolate mofetil (MMF) with improve-
ment of his renal function (sCr 106 μmol/L), proteinuria
(0.2 g/24 hours) and a reduction in MPO- ANCA titre
(10.5 IU/ml).
Case 6
A 60 year old woman was diagnosed with seropositive
RA, after developing symmetrical polyarthritis of the
metacarpophalangeal joints and wrists. She was treated
with hydroxychloroquine (HCQ), MTX and leflunomide.
Disease control was poor, but the patient refused bio-
logic therapy. Seven years later, she presented with
haematuria, proteinuria (1.6 g/24 hours) and decline in
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started hemodialysis. She had an acute phase response
(CRP 91 mg/L, ESR 27 mm/h). The RhF was negative.
She was ANCA negative, but a renal biopsy demonstrated
pauci-immune focal necrotizing glomerulonephritis with
moderate chronic damage. A clinical diagnosis of MPATable 1 Case reports published describing an overlap betwee
Year/Cases Diagnoses Age
RA
Age
VAS
Vasculiti
symptom
1974/1 (Pritchard 1976) RA/GPA 40 59 ENT
1976/2 (Ohashi et al. 1992) RA/GPA 45 45 ENT
RA/GPA 73 75 ENT, Eyes
11992/1 (Steuer et al. 1995) RA/GPA 33 38 ENT
1995/1 (Harper et al. 1997) RA/MPA 49 62 Lung,Kidn
1997/10 (Messiaen et al. 1998) RA/MPA 31-62 NA 5: kidney
1: kidney
3: kidney
1:kidney,
skin
1999/1 (Yorioka et al. 1999) RA/MPA 22 24 Kidney
2002/2 (Chinoy &
McKenna 2002)
RA/GPA 32 32 ENT, Lun
RA/GPA *41 26 Lung
2003/2 (Douglas et al. 2003) RA/GPA 36 37 ORL, Lun
RA/GPA 35 55 Lung
2005/1 (Goto et al. 2005) RA/MPA 44 48 ORL, eye
2008/1 (Pai & Panda 2008) RA/GPA 57 60 Lung
2012/4 (Szilasi et al. 2012) RA/GPA 40 70 Lung, Kid
RA/MPA *49 44 Lung, Kid
RA/MPA 28 34 Lung, Kid
RA/EGPA 52 54 Skin
2012/1 (Vaishnav et al. 2012) RA/GPA 36 37 Lung
2013/1 (Reitblat & Reitblat
2013)
RA/GPA 45 58 Kidney
2014/1 (Ortiz-Sierra et al. 2014) RA/GPA 65 67 Skin, lung
ENT, eye
Our report 5 RA/MPA 24-63 63-69 1: Kidney
1 RA/GPA 5: Kidney
RA: Rheumatoid Arthritis, GPA: Granulomatosis with polyangiitis, MPA: Microscopic
HCQ: hydroxychloroquine, NSAID: non-steroidal anti-inflammatory drug, CP: cyclop
D: dead, I: AAV improved, HD: Hemodialysis.was made. She was treated with oral cyclophosphamide
and prednisolone, but did not recover independent renal
function. One year later, she died following an episode of
a severe sepsis.
Overall, in our six patients there was a median delay
of 10.5 years (range 4–43 years) between RA and AAVn ANCA associated vasculitis and rheumatoid arthritis
s
s
Positive
antibodies
RA therapy Follow-up
RhF, ANA Gold, tuberculin
injections, NSAID
D
RhF HCQ, aspirin I
, Lung RhF Gold, NSAID I
RhF NSAID, Gold I
ey RhF, ANA,
p-ANCA
NSAID, Gold, SFZ I
only 4: p-ANCA 6: NSAID 4 D
, lung, eye 9: RhF 1: NSAID, Penicillamine HCQ 2 HD
, skin 6: ANA 1: Prednisone, SFZ, Gold 4 I
bowel, 1: HCQ
1: HCQ, SFZ
RhF, ANA,
MPO-ANCA
NSAID I
g, Kidney p-ANCA Prednisolone, NSAID, CYC I
p-ANCA I
g, Kidney RhF, PR3-ANCA Prednisolone, MTX, NSAID. I
RhF, PR3-ANCA NSAID, MTX I
s, Kidney MPO-ANCA,
RhF, ANA
MTX, Penicillamine,
Gold, prednisolone
I
RhF, Anti-CCP,
PR3-ANCA
HCQ, prednisolone I
ney PR3-ANCA,
Anti-CCP,RhF
Prednisolone I
ney MPO-ANCA, RhF Adalimumab, RTX I
ney MPO-ANCA, RhF Prednisone, SFZ, MTX I
MPO-ANCA, RhF MTX, Cyclosporine I
c-ANCA, RhF D
PR3-ANCA, RhF MTX, Etanercept HD
, RhF, c-ANCA MTX, Prednisone, etanercept, I
, lung 3: RhF 1: MTX, prednisone 5 I
1: Anti-CCP 1: SFZ 1 HD
1: PR3-ANCA 1: HCQ, MTX, leflunomide 1D
3: MPO-ANCA 1: Infliximab, MTX, SFZ
1: Etanercept, MTX, SFZ,
AZA
1: Prednisolone
polyangiitis, EGPA (Churg-Strauss Syndrome), ENT: ear, nose and throat;
hophamide; AZA: Azathioprine, SFZ: sulfasalazine, MTX: methotrexate,
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the AAV. All had significant renal involvement with
AAV, displaying a typical focal and segmental glomerulo-
nephritis, and a clinical diagnosis of MPA predominated.
Half were RhF positive at the time of AAV diagnosis,
and there was a predominance of MPO-ANCA positiv-
ity, as is frequently found in overlap syndromes involv-
ing AAV.
Discussion
We described six patients with rheumatoid arthritis who
subsequently developed AAV, mostly with MPA. In
addition, we performed a literature search using the
terms ANCA, vasculitis and rheumatoid arthritis and
found a total of 29 case reports describing this associ-
ation between AAV and RA (Table 1). Of these cases, 13
patients had an overlap between RA and GPA, 15 RA
and MPA and only 1 with RA and EGPA. In all cases,
except two, ANCA vasculitis was diagnosed after RA. Of
the 29 cases published, 19 patients presented with renal
dysfunction, 15 with MPA and 4 with GPA. Immuno-
logical testing demonstrated that 26 patients were RhF
positive at presentation, while 7 were c-ANCA or PR3-
ANCA positive and, 11 were p-ANCA or MPO-ANCA
positive. Seven were ANCA negative. Interestingly, ten
patients were also ANA positive, suggesting a broader
immune dysfunction.
With regards treatment, for RA we found that hydro-
xychloroquine, methotrexate, prednisolone and anti-
TNF-alpha monoclonal antibodies were most commonly
used, while for AAV, cyclophosphamide, pulsed methyl-
prednisolone, and oral prednisolone were most com-
monly used induction therapies followed by azathioprine
as remission maintenance therapy.
Possible reasons for the association between systemic
ANCA associated vasculitis and RA may be the common
genetic predispositions to autoimmunity which involve
the HLA region or genes such as PTPN22, reported in
series of both RA and AAV (Jagiello et al. 2005; Farago
et al. 2009; Johansson et al. 2006; Lee et al. 2005). In
addition, Rocatello et al (Menegattia et al. 2009) showed
that polymorphisms in uteroglobin (a multifunctional
protein with anti-inflammatory properties) and NF-κB2
(a transcription factors that regulates the expression of a
wide range of immune response genes) were associated
with a genetic predisposition towards developing both
vasculitis and RA.
However, another possibility is the use of TNF antago-
nists which may have predisposed to development of
secondary autoimmune disease. A French nationwide
survey identified 39 cases of vasculitis induced following
use of TNF antagonists (Saint Marcoux & De Bandt
2006), while a larger series of 379 cases of anti-TNF agent-
induced autoimmune diseases and identified 118 patientswith vasculitis, most of whom only showed cutaneous
leukocytoclastic vasculitis, and 11 (9.3 %) were positive for
ANCA (Ramos-Casals et al. 2008). In our study, only 2
patients were treated with anti-TNF alpha (infliximab and
etanercept) and subsequently developed MPA.
In summary we have reviewed a total of 35 cases of
ANCA associated systemic vasculitis associated with
RA and suggest that this may be a rare form of an AAV
autoimmune overlap, which includes anti-GBM disease
(Weber et al. 1992; Kalluri et al. 1997), scleroderma
(Derrett-Smith et al. 2013), SLE (Tetikkurt et al. 2012) and
membranous glomerulonephritis (Gaber et al. 1993; Tse
et al. 1997). Its recognition could lead to timely antibody
screening of patients with the relevant clinical scenario
and a more rapid initiation of appropriate management.
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